Areteia Therapeutics introduces dexpramipexole, a novel oral drug in Phase 3 trials for asthma and COPD, aiming for approval ...

Matthew Moll, MD, MPH, and Michael H. Cho, MD, MPH, from the Department of Medicine at Brigham and Women's Hospital are ...

CAMBRIDGE, MA, USA; ROTTERDAM, The Netherlands and SHANGHAI, China I 4, 2025 I Harbour BioMed (HKEX: 02142, the "Company"), a global ...

In a recent study, Mass General Brigham researchers demonstrated that through low-cost genetic samples, that can be obtained from a cheek swab or blood test, they can improve identification of people ...

Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...

This is the first major breakthrough in 50 years. British researchers have just discovered a new treatment for severe forms ...

A new study highlights the multiple obstacles patients face before receiving a chronic obstructive pulmonary disease ...

Upgrades aim to improve asthma relief and COPD treatment with advanced technology.United States, January 31, 2025 -- TruNeb ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

During and after an exacerbation, mental recovery involves taking care of both your physical and mental health. Resting, ...